Chabaksin Research Institute Signs Agreement with Algenomics for Next-Generation RNA Vaccine Development

[Asia Economy Reporter Chunhee Lee] Cha Vaccine Institute is partnering with Algenomics to develop next-generation ribonucleic acid (RNA) vaccines.

Cha Vaccine Institute, a subsidiary of Cha Biotech, announced on the 9th that it has signed an agreement with Algenomics for the joint development of next-generation RNA platform-based vaccines. Going forward, the two companies plan to jointly research and develop next-generation RNA vaccines and collaborate on the exchange of necessary physical and human resources during this process.

Next-generation RNA vaccines are an advanced technology of messenger RNA (mRNA) vaccines, which have become the mainstream for COVID-19 vaccines. These next-generation RNA vaccines are produced based on nonlinear RNA structures, offering greater stability and longer-lasting efficacy compared to linear mRNA vaccines.

Cha Vaccine Institute will select target diseases for the vaccines and design appropriate antigens accordingly. Algenomics will be responsible for producing, optimizing, manufacturing, and process development of RNA vaccines expressing the antigens designed by Cha Vaccine Institute, based on its proprietary nonlinear RNA structure platform. Cha Vaccine Institute will conduct preclinical studies on vaccines developed using ‘Lipo-pam’ as the delivery material for RNA vaccines and derive vaccine candidates.

Currently, Cha Vaccine Institute has independently developed and possesses the immune adjuvant ‘L-pampo’ and Lipo-pam, which are necessary for manufacturing recombinant protein vaccines. Utilizing these, it is conducting clinical development of preventive and therapeutic vaccines for infectious diseases such as hepatitis B and shingles.

Algenomics is an RNA-based drug development company that develops anticancer drugs and treatments for degenerative and genetic diseases based on a mechanism that edits target RNA causing disease with RNA editing enzymes and generates therapeutic RNA in its place. The company also owns proprietary nonlinear RNA structure platform technology.

Yeom Jeong-seon, CEO of Cha Vaccine Institute, said, “The collaboration between two companies with their own unique technologies will facilitate the development of next-generation vaccine platforms and new pipelines utilizing them,” adding, “Through this agreement, we will expand our business into new areas such as RNA vaccines.” Lee Sung-wook, CEO of Algenomics, also stated, “We expect the development of next-generation vaccines based on our new RNA structure technology to accelerate,” and “We will demonstrate the versatility, applicability, and excellence of Algenomics’ proprietary RNA platform technology as innovative therapeutics and next-generation vaccines.”

This content was produced with the assistance of AI translation services.